MBI Researchers identify new immunotherapy targets for medulloblastoma
McKnight Brain Institute of the University of Florida shared on LinkedIn:
“MBI researchers led a study published today in Genome Medicine analyzing genetic data from 170 medulloblastoma patients across four subtypes to identify potential new targets for immunotherapy treatment of the disease.
‘This work provides a foundation for developing more personalized immunotherapies that could be safer and more effective than current treatments,’ said first author Dr. Changlin Yang.”
‘Identification of tumor rejection antigens and the immunologic landscape of medulloblastoma‘
Authors: Changlin Yang, Vrunda Trivedi, Kyle Dyson, Tongjun Gu, Kate M. Candelario, Oleg Yegorov and Duane A. Mitchell
Source: McKnight Brain Institute of the University of Florida/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023